Difference between revisions of "Dey N, et al. Pharmacol. Ther. (2017) cited as Ref 362 in DOI: 10.1038/s41392-020-0110-5 (Q9625)"
Jump to navigation
Jump to search
(Created claim: title (P93): PI3K-AKT-mTOR inhibitors in breast cancers: from tumor cell signaling to clinical trials, #quickstatements; #temporary_batch_1590010982689) |
(Created claim: Page(s) (P105): 91-106, #quickstatements; #temporary_batch_1590074839150) |
||
| Property / Page(s) | |||
| + | 91-106 | ||
| Property / Page(s): 91-106 / rank | |||
| + | Normal rank | ||
Latest revision as of 15:39, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Dey N, et al. Pharmacol. Ther. (2017) cited as Ref 362 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Dey N
0 references
De P
0 references
Leyland-Jones B
0 references
2017
0 references
Pharmacol. Ther.
0 references
175
0 references
PI3K-AKT-mTOR inhibitors in breast cancers: from tumor cell signaling to clinical trials (English)
0 references
91-106
0 references
